Astec LifeSciences Limited — Board Meeting, 27-01-2025: Outcome of Board Meeting

The Board of Directors has approved the unaudited financial results for the quarter and nine months ended 31st December 2024, reflecting significant challenges with a consolidated net loss of ₹40.40 crore. They noted an unmodified review report from statutory auditors. Furthermore, Mr. R. R. Govindan has been re-appointed as a Non-Executive & Independent Director for a second term, to be confirmed by shareholders via postal ballot. The Board also approved an equity investment of up to ₹3.75 crore in a special purpose vehicle for solar power generation, reinforcing its commitment to renewable energy.